12 research outputs found
Antioxidant Thymoquinone and Its Potential in the Treatment of Neurological Diseases
Oxidative stress is one of the main pathogenic factors of neuron damage in neurodegenerative processes; this makes it an important therapeutic target to which the action of neuroprotectors should be directed. One of these drugs is thymoquinone. According to modern data, this substance has a wide range of pharmacological activity, including neuroprotective, which was demonstrated in experimental modeling of various neurodegenerative diseases and pathological conditions of the brain. The neuroprotective effect of thymoquinone is largely due to its antioxidant ability. Currently available data show that thymoquinone is an effective means to reduce the negative consequences of acute and chronic forms of cerebral pathology, leading to the normalization of the content of antioxidant enzymes and preventing an increase in the level of lipid peroxidation products. Antioxidant properties make this substance a promising basis for the development of prototypes of therapeutic agents aimed at the treatment of a number of degenerative diseases of the central nervous system
Mitochondria-Targeted Antioxidants as Potential Therapy for the Treatment of Traumatic Brain Injury
The aim of this article is to review the publications describing the use of mitochondria-targeted antioxidant therapy after traumatic brain injury (TBI). Recent works demonstrated that mitochondria-targeted antioxidants are very effective in reducing the negative effects associated with the development of secondary damage caused by TBI. Using various animal models of TBI, mitochondria-targeted antioxidants were shown to prevent cardiolipin oxidation in the brain and neuronal death, as well as to markedly reduce behavioral deficits and cortical lesion volume, brain water content, and DNA damage. In the future, not only a more detailed study of the mechanisms of action of various types of such antioxidants needs to be conducted, but also their therapeutic values and toxicological properties are to be determined. Moreover, the optimal therapeutic effect needs to be achieved in the shortest time possible from the onset of damage to the nervous tissue, since secondary brain damage in humans can develop for a long time, days and even months, depending on the severity of the damage
The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk.
BACKGROUND: Many ischemia-induced neurological pathologies including stroke are associated with high oxidative stress. Mitochondria-targeted antioxidants could rescue the ischemic organ by providing specific delivery of antioxidant molecules to the mitochondrion, which potentially suffers from oxidative stress more than non-mitochondrial cellular compartments. Besides direct antioxidative activity, these compounds are believed to activate numerous protective pathways. Endogenous anti-ischemic defense may involve the very powerful neuroprotective agent erythropoietin, which is mainly produced by the kidney in a redox-dependent manner, indicating an important role of the kidney in regulation of brain ischemic damage. The goal of this study is to track the relations between the kidney and the brain in terms of the amplification of defense mechanisms during SkQR1 treatment and remote renal preconditioning and provide evidence that the kidney can generate signals inducing a tolerance to oxidative stress-associated brain pathologies. METHODOLOGY/PRINCIPAL FINDINGS: We used the cationic plastoquinone derivative, SkQR1, as a mitochondria-targeted antioxidant to alleviate the deleterious consequences of stroke. A single injection of SkQR1 before cerebral ischemia in a dose-dependent manner reduces infarction and improves functional recovery. Concomitantly, an increase in the levels of erythropoietin in urine and phosphorylated glycogen synthase kinase-3β (GSK-3β) in the brain was detected 24 h after SkQR1 injection. However, protective effects of SkQR1 were not observed in rats with bilateral nephrectomy and in those treated with the nephrotoxic antibiotic gentamicin, indicating the protective role of humoral factor(s) which are released from functional kidneys. Renal preconditioning also induced brain protection in rats accompanied by an increased erythropoietin level in urine and kidney tissue and P-GSK-3β in brain. Co-cultivation of SkQR1-treated kidney cells with cortical neurons resulted in enchanced phosphorylation of GSK-3β in neuronal cells. CONCLUSION: The results indicate that renal preconditioning and SkQR1-induced brain protection may be mediated through the release of EPO from the kidney
SkQR1 and RRPC provide some features of ischemic tolerance.
<p>(<b>A</b>) Changes in erythropoietin (EPO) level in the daily urine. 1 or 2 µmol/kg SkQR1 was injected i/p 24 h before urine collection. Rats were subjected to RRPC for 24 h and gentamicin for 6 days prior to urine collection. (<b>B</b>) Detection of phosphorylated glycogen synthase kinase-3β (P-GSK-3β) in the total brain tissue. Representative Western blots with corresponding densitometry averaged over 6 blots are shown. Band densities were normalized to the density of total GSK-3β band. 1 µmol/kg SkQR1 was injected i/p 24 h before excising the brain. (<b>C1–4</b>) Detection of P-GSK-3β in cultured cortical neurons (CNs) after co-culturing with renal tubular cells (RTC) treated with 250 nM SkQR1 for 1 h before 24 h of co-culturing (C1); control CNs (C2); co-culture of CNs and RTC (C3); co-culture of CNs with RTC primed with SkQR1 (C4). (<b>D</b>) Detection of P-GSK-3β in the cultural glial cells treated with 50 or 100 nM SkQR1 for 24 h. (<b>E</b>) Detection of EPO in the entire brain tissue. Densitometry of Western EPO spots averaged over 6 blots is shown. 1 µmol/kg SkQR1 was injected i/p 3 or 24 h before excising the brain. * Denotes significantly different from the control group (p<0.05) (One-way ANOVA, followed by Tukey’s post hoc analysis or <i>t</i> tests for independent samples).</p
Neurological state<sup>a</sup>.
a<p>The neurological state scores are recorded in a blind fashion and expressed as median and interquartile ranges, the 25th to 75th percentile are shown in the parentheses. Baseline represents neurological state of intacte rats. *Denotes significant from the score at 24 h after the MCAO compared to MCAO+ VEHICLE or MCAO groups (p<0.05) (Kruskal-Wallis test with the Mann–Whitney <i>u</i>-test with Bonferroni correction post hoc or Mann–Whitney test when comparing between two groups).</p
Hematological parameters<sup>a</sup>.
a<p>Hematological parameters changes after treatment with 2 µmol/kg SkQR1 for 12 h: Vehicle (n = 8) and SkQR1 (n = 8); for 24 h: Vehicle (n = 6) and SkQR1, (n = 7). RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit.</p>*<p>Denotes significantly different from the vehicle group (p<0.05) (<i>t</i> tests).</p
Bilateral nephrectomy and gentamicin pretreatment abolish neuroprotective action of SkQR1 and RRPC.
<p>The effects of SkQR1 after bilateral nephrectomy on the brain infarct volume and brain swelling of rats exposed to MCAO are shown in (A, B) and (C) correspondingly. Nephrotoxic gentamicin pretreatment shows similar abrogation of beneficial effects of SkQR1 and RRPC on the brain infarct volume (D, E) and brain swelling (F) of rats exposed to MCAO. (A, D) Representative T2-weighted MR-images from coronal brain sections (0.5 mm thick, from rostral (top) towards caudal (bottom)) obtained 24 h after reperfusion. Hyperintensities regions refer to ischemic areas. The evaluation of the brain damage area and brain swelling were done by using MRI with analysis of T2-weighted images.</p
SkQR1 accumulates in kidney but not in brain.
<p>SkQR1 retention and distribution over kidney and brain compartments 3 and 24 hrs after i/p injection of 1 µmol/kg SkQR1. Confocal microscopy of tissues slices. As a negative control, organs from untreated animals were also analyzed. Bar, 50 µm.</p